Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, bel-sar, for the first-line treatment of adult patients with early-stage choroidal melanoma will be presented at the upcoming American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023, in San Francisco.

Details for the paper presentation are as follows:

Title: A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration
Presenter: Carol L. Shields, MD, Wills Eye Hospital
Session #: PA069
Location #: WEST 2006
Date/Time: Monday, November 6, 2023, from 2:54 p.m. to 3:01 p.m. Eastern Time (11:54 a.m. to 12:01 p.m. Pacific Time)

The presentation will be available here on Monday, November 6, 2023, following the presentation.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting, anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer. Aura is headquartered in Boston, MA.

For more information, visit aurabiosciences.com, or follow us on Twitter and LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031579720/en/

The Aura Biosciences Stock at the time of publication of the news with a raise of +10,04 % to 8,22USD on Nasdaq stock exchange (31. Oktober 2023, 20:55 Uhr).